Xylometazoline
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Common Cold
Conditions
Common Cold
Trial Timeline
Mar 1, 2007 → Apr 1, 2007
NCT ID
NCT00452270About Xylometazoline
Xylometazoline is a phase 3 stage product being developed by Novartis for Common Cold. The current trial status is completed. This product is registered under clinical trial identifier NCT00452270. Target conditions include Common Cold.
What happened to similar drugs?
5 of 16 similar drugs in Common Cold were approved
Approved (5) Terminated (3) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00452270 | Phase 3 | Completed |
Competing Products
20 competing products in Common Cold